机构:[1]Department of Critical-care Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China大德路总院重症医学科大德路总院重症医学科广东省中医院[2]Guangzhou Key Laboratory of Myocardial Infarction in Chinese Medical Prevention and Treatment, Guangzhou, China[3]Cardiac Electrophysiology Research Team, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[4]New Patent Chinese Medicine and Decoction Pieces Innovative Research and Development Team, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China广东省中医院深圳市中医院深圳医学信息中心
Tongguan capsule is a compound Chinese medicine used to treat ischaemic heart diseases. This study aimed to investigate whether Tongguan capsule-derived herb (TGD) has a preventive effect on atrial fibrillation (AF) in post-myocardial infarction (MI) rats and to determine the underlying mechanisms. MI was induced by ligation of the left anterior descending coronary artery. TGD was administered to the post-MI rats over a 4-week period. The TGD-treated rats had lower rates of AF inducibility and shorter AF durations than the MI rats. TGD improved the left atrial (LA) conduction velocity and homogeneity. It reduced the fibrosis-positive areas and the protein levels of collagen types I and III in the left atrium. In vitro, it inhibited the expression of collagen types I and III by inhibiting the proliferation, migration, differentiation and cytokine secretion of cardiac fibroblasts (CFs). In conclusion, the current study demonstrated that TGD reduces susceptibility to AF and improves LA conduction function in rats with post-MI by inhibiting left atrial fibrosis and modulating CFs. Targeting the CF population may be a novel antiarrhythmic therapeutic approach.
基金:
National Natural Science Foundation of
China, Grant/Award Number: 81503394;
Guangzhou Science and Technology
Foundation, Grant/Award Number:
201607010364; Natural Science Foundation
of Guangdong Province, Grant/Award
Number: 2015A030313354,
2016A030313634, 2017A030313888;
Guangdong Science and Technology
Foundation, Grant/Award Number:
2014A020221026; Guangdong Provincial
New Chinese Medicine Research and
Development Project in 2015; The Specific Research Fund for TCM Science and
Technology of Guangdong Provincial
Hospital of Chinese Medicine, Grant/Award
Number: YN2018MJ02
第一作者机构:[1]Department of Critical-care Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China[2]Guangzhou Key Laboratory of Myocardial Infarction in Chinese Medical Prevention and Treatment, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Critical-care Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China[2]Guangzhou Key Laboratory of Myocardial Infarction in Chinese Medical Prevention and Treatment, Guangzhou, China[*1]Department of Critical-care Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
推荐引用方式(GB/T 7714):
Ma Shiyu,Ma Jin,Guo Liheng,et al.Tongguan capsule-derived herb reduces susceptibility to atrial fibrillation by inhibiting left atrial fibrosis via modulating cardiac fibroblasts[J].JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2019,23(2):1197-1210.doi:10.1111/jcmm.14022.
APA:
Ma, Shiyu,Ma, Jin,Guo, Liheng,Bai, Junqi,Mao, Shuai&Zhang, Minzhou.(2019).Tongguan capsule-derived herb reduces susceptibility to atrial fibrillation by inhibiting left atrial fibrosis via modulating cardiac fibroblasts.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,23,(2)
MLA:
Ma, Shiyu,et al."Tongguan capsule-derived herb reduces susceptibility to atrial fibrillation by inhibiting left atrial fibrosis via modulating cardiac fibroblasts".JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 23..2(2019):1197-1210